SCLXWHIGH SIGNALRISK10-K

SCLXW has executed a complete business transformation from pharmaceutical operations to cryptocurrency treasury strategy, accompanied by deteriorating financial performance.

The company has abandoned its previous pharmaceutical business model (removing all references to drug development, clinical trials, and sales force) and pivoted to a cryptocurrency investment strategy focused on bitcoin and Ethereum. This represents a fundamental change in business risk profile and investment thesis. The dramatic reduction in outstanding shares from 243 million to 8.5 million suggests a significant reverse stock split or restructuring event that investors should investigate.

Comparing 2026-04-10 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

The financial picture shows a company under considerable stress, with revenue declining meaningfully to $30.3M while current liabilities grew substantially to $483.7M. Operating cash flow deteriorated significantly to just $3.8M, though the company did reduce interest expense considerably from $9.6M to $1.1M. The doubling of inventory alongside declining accounts receivable suggests operational challenges, while the modest increase in cash provides limited cushion against the substantially higher liability burden.

FINANCIAL STATEMENT CHANGES
Inventory
Balance Sheet
+96.6%
$2.4M→$4.8M

Inventory surged 96.6% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Interest Expense
P&L
-88.9%
$9.6M→$1.1M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Current Liabilities
Balance Sheet
+86.3%
$259.6M→$483.7M

Current liabilities surged 86.3% — significant near-term obligations; verify ability to meet short-term debt.

Operating Cash Flow
Cash Flow
-80.3%
$19.3M→$3.8M

Operating cash flow fell 80.3% — earnings quality concerns; investigate working capital changes and non-cash items.

Cash & Equivalents
Balance Sheet
+51.4%
$3.3M→$5.0M

Cash position surged 51.4% — strong cash generation or capital raise providing significant financial cushion.

Revenue
P&L
-46.5%
$56.6M→$30.3M

Revenue declined 46.5% — significant demand weakness or market share loss warrants investigation.

Accounts Receivable
Balance Sheet
-42.3%
$26.4M→$15.2M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Gross Profit
P&L
-24.9%
$167.4M→$125.8M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

LANGUAGE CHANGES
NEW — 2026-04-10
PRIOR — 2025-03-31
ADDED
As of April 2, 2026, the registrant had 8,491,267 shares of common stock, par value $0.0001 per share, outstanding.
We have adopted a cryptocurrency treasury strategy in which we intend to invest in bitcoin, Ethereum and other blockchain-linked cryptocurrencies.
We intend to accumulate such cryptocurrencies as a long-term treasury asset.
Our goal is to acquire and grow our overall cryptocurrency position and utilize professional treasury strategies to both increase our cryptocurrency holdings, while driving revenue via a range of staking and related yield-generating activities.
In the future, we plan to evaluate additional cryptocurrency holdings and transactions, including but not limited to strategic investments and/or acquisitions of operating companies that we view as aligned with our cryptocurrency treasury strategy.
+7 more — sign up free →
REMOVED
As of March 25, 2025, the registrant had 243,312,885 shares of common stock, par value $0.0001 per share, outstanding.
Our Product Candidates We acquired SP-102 from Semnur Pharmaceuticals, Inc.
We leverage a sales force of over 70 people, targeting over 10,000 primary care physicians, pain specialists, neurologists, rheumatologist, and palliative care physicians who we believe treat the majority of PHN patients.
We are developing SEMDEXA to address the limitations associated with the available corticosteroid epidural injectable products that are used off-label.
We have extensive clinical and pre-clinical data (including those obtained from multiple Phase 2 clinical trials) with the novel viscous gel formulation of SP-102.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →